{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:12:06Z","timestamp":1789132326852,"version":"build-2803163510"},"reference-count":101,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the use of aripiprazole in children and adolescents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Medline and Embase databases were systematically searched using the keywords\n                      <jats:italic toggle=\"yes\">aripiprazole<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">child<\/jats:italic>\n                      or\n                      <jats:italic toggle=\"yes\">adolescent<\/jats:italic>\n                      over the period from 2000 to 2019. The initial screen yielded 163 publications, from which 99 studies were reviewed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Aripiprazole is one of the most widely prescribed atypical antipsychotics. Like others, its use in children and adolescents is becoming commonplace and occurs in off-label indications. Aripiprazole has proven efficacy for several indications in children and adolescents, including schizophrenia, bipolar disorder, Tourette's syndrome, and behavioral impairments associated with autism and intellectual disability. Adverse effects are more important in children and adolescents than adults, particularly weight gain, drowsiness, extrapyramidal effects, and metabolic effects, even though the latter may appear less important than with other atypical antipsychotics. Severe adverse effects often occur in multiple-prescription settings. At present, postprescription monitoring is very poor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Aripiprazole has proven efficacy for several indications in children and adolescents. However, its use requires clinical and paraclinical monitoring to assess the occurrence of adverse events that may challenge the benefit\/risk ratio. In addition, off-label prescriptions should be limited, as they appear to account for a significant proportion of aripiprazole use worldwide.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2020.0014","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T12:57:41Z","timestamp":1600174661000},"page":"4-32","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":38,"title":["Aripiprazole in Children and Adolescents"],"prefix":"10.1177","volume":"31","author":[{"given":"Nicolas","family":"Coustals","sequence":"first","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, APHP, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Universit\u00e9 Sorbonne, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Line","family":"M\u00e9nard","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Children\u2019s Hospitals of Nice CHU-Lenval, Nice, France."},{"name":"CoBTek, EA7276, University of C\u00f4te d\u2019Azur, Nice, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, APHP, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Universit\u00e9 Sorbonne, Paris, France."},{"name":"Institut des Syst\u00e8mes Intelligents et Robotiques, CNRS UMR 7222, Universit\u00e9 Sorbonne, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,2,11]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10578-016-0694-8"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2015.0141"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-013-0016-6"},{"key":"e_1_3_3_5_1","first-page":"25","article-title":"Antipsychotic prescription in children and adolescents","volume":"111","author":"Bachmann CJ","year":"2014","unstructured":"Bachmann CJ, , Lempp T, , Glaeske G, , Hoffmann F: Antipsychotic prescription in children and adolescents. Dtsch \u00c4rztebl Int, 111:25\u201334, 2014.","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2018.12.007"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2017.0059"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2017.09.001"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2015.06.015"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0626-4"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2431-11-40"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3182549259"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rasd.2012.08.001"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/0706743717751693"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurenf.2016.10.002"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.28.5.w770"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2010.09.011"},{"key":"e_1_3_3_18_1","first-page":"597","article-title":"Clinical experience of long-term treatment with Aripiprazole (Abilify) in children and adolescents at the child and adolescent psychiatric clinic 1 in Roskilde, Denmark","volume":"72","author":"Diom\u0161ina B","year":"2015","unstructured":"Diom\u0161ina B, , Rasmussen PD, , Danilevi\u010di\u00fct\u0117 V: Clinical experience of long-term treatment with Aripiprazole (Abilify) in children and adolescents at the child and adolescent psychiatric clinic 1 in Roskilde, Denmark. Acta Pol Pharm, 72:597\u2013606, 2015.","journal-title":"Acta Pol Pharm"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-2970"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2014.0128"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1286348"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2018.0115"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1542\/pir.2017-0044"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12042"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2008.0111"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13m08500"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2010.0102"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.07061035"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2007.0124"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11m07104"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2016.0160"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-2851K"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2013.10.020"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12991-016-0112-4"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10578-013-0390-x"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000223"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2017.07.001"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2016.07.011"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedhc.2011.10.009"},{"key":"e_1_3_3_40_1","first-page":"6","article-title":"Aripiprazole for autism spectrum disorders (ASD)","volume":"009043","author":"Hirsch LE","year":"2016","unstructured":"Hirsch LE, , Pringsheim T: Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev, CD009043:6, 2016.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2011.0129"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2015.0135"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.12607"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10578-016-0704-x"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000320"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000548"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2014.10.002"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2017.0152"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.10453"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.2017.15.3.285"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-016-0183-3"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/pan.13154"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2015.0125"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S174622"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2012.0075"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/CHI.0b013e3181b76658"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2009.0121"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09m05933"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1475-6773.2012.01461.x"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181c92eb2"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-015-0688-2"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.4103\/0976-3147.165355"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-017-2406-0"},{"key":"e_1_3_3_64_1","unstructured":"Nevo ON Mehta SH Chan V Gill R Kortepeter C Chai GP: Pediatric postmarketing pharmacovigilance and drug utilization review: Abilify (aripiprazole). 2017. https:\/\/www.fda.gov\/media\/107289\/download (accessed April9 2019)."},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2012.647"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2009.09.003"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbq172"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-3782"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000639"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2018.0068"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.108322"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000342"},{"key":"e_1_3_3_73_1","article-title":"Aripiprazole-induced parkinsonism in a child: A case report","volume":"13","author":"Patel H","year":"2011","unstructured":"Patel H, , Patel A, , Mushtaq S, , Haq F, , Raza S: Aripiprazole-induced parkinsonism in a child: A case report. Prim Care Companion CNS Disord, 13:PCC.10l01081, 2011.","journal-title":"Prim Care Companion CNS Disord"},{"key":"e_1_3_3_74_1","first-page":"101","article-title":"The off-label prescription in child and adolescent psychiatry","volume":"94","author":"Perraudin M","year":"2018","unstructured":"Perraudin M, , Coulon S, , Willoquet G, , Welniarz B: The off-label prescription in child and adolescent psychiatry. L\u2019information Psychiatrique, 94:101\u2013107, 2018.","journal-title":"L\u2019information Psychiatrique"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2015.0128"},{"key":"e_1_3_3_76_1","first-page":"22","article-title":"A review of the French Pharmacovigilance Database","volume":"1","author":"Poudroux E","year":"2018","unstructured":"Poudroux E, , Lebrun J, , Clarivet B, , Bres V, , Hillaire-Buys D, , Pinzani Centre V. Atypical antipsychotic misuse and adverse events: A review of the French Pharmacovigilance Database. Fund Clin Pharmacol 32(Suppl, 1):22, 2018.","journal-title":"Fund Clin Pharmacol 32(Suppl"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2018.0092"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000760"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.2165\/11592020-000000000-00000"},{"key":"e_1_3_3_80_1","first-page":"218","article-title":"Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth","volume":"20","author":"Pringsheim T","year":"2011","unstructured":"Pringsheim T, , Panagiotopoulos C, , Davidson J, , Ho J; CAMESA Guideline Group: Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry, 20:218\u2013233, 2011b.","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-0828"},{"key":"e_1_3_3_82_1","first-page":"1","article-title":"Second generation antipsychotics in \u201creal-life\u201d","volume":"2","author":"Rafaniello C","year":"2016","unstructured":"Rafaniello C, , Pozzi M, , Pisano S, , Ferrajolo C, , Bertella S, , Sportiello L, , Carnovale C, , Sullo MG, , Cattaneo D, , Gentili M, , Rizzo R, , Pascotto A, , Mani E, , Villa L, , Riccio MP, , Sperandeo S, , Bernardini R, , Bravaccio C, , Clementi E, , Molteni M, , Rossi F, , Radice S, , Capuano A: Second generation antipsychotics in \u201creal-life\u201d. paediatric patients. Adverse drug reactions and clinical outcomes of drug switch. Expert Opin Drug Saf 15(Suppl, 2):1\u20138, 2016.","journal-title":"paediatric patients. Adverse drug reactions and clinical outcomes of drug switch. Expert Opin Drug Saf 15(Suppl"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.5812\/ijp.60087"},{"key":"e_1_3_3_84_1","article-title":"Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6\u201317 years old): Results from a pooled analysis of 2 studies","volume":"13","author":"Robb AS","year":"2011","unstructured":"Robb AS, , Andersson C, , Bellocchio EE, , Manos G, , Rojas-Fernandez C, , Mathew S, , Marcus R, , Owen R, , Mankoski R: Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6\u201317 years old): Results from a pooled analysis of 2 studies. Prim Care Companion CNS Disord, 13:PCC.10m01008, 2011.","journal-title":"Prim Care Companion CNS Disord"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2015.0285"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2016.0026"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1097\/PEC.0000000000001000"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2011.0134"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2016.1233342"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2012.0038"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e3182767efb"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04726"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2017.1371012"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.02.023"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2015.0104"},{"key":"e_1_3_3_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2017.04.013"},{"key":"e_1_3_3_97_1","doi-asserted-by":"crossref","unstructured":"Winterfeld U Heuzey M-FL Acquaviva E Mouren M-C Brion F Bourdon O: Off-label use of psychotropic drugs in paediatrics: a prospective study. 2009. \/data\/revues\/0929693X\/v16i9\/S0929693X0900267X https:\/\/www.em-consulte.com\/en\/article\/223988 (accessed April9 2019).","DOI":"10.1016\/j.arcped.2009.06.012"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-015-0504-z"},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.12m08189"},{"key":"e_1_3_3_100_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2016.0049"},{"key":"e_1_3_3_101_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2498"},{"key":"e_1_3_3_102_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.3493"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2020.0014","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2020.0014","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2020.0014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:55:55Z","timestamp":1777388155000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2020.0014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1089\/cap.2020.0014"],"URL":"https:\/\/doi.org\/10.1089\/cap.2020.0014","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}